General Proximity, a San Francisco-based biotech platform founded in 2019, has raised $16 million in seed funding led by Aydin Senkut of Felicis, with additional support from Y Combinator, age1, Modi Ventures, and Wilson Sonsini. The funding will expedite the development of treatments targeting undruggable proteins linked to cancer, cardiometabolic diseases, neurodegeneration, and longevity. Senkut expressed confidence in General Proximity’s innovative approach to drug discovery, emphasizing its potential to address significant health challenges and enhance human healthspan. Felicis manages over $3 billion in capital, focusing on early-stage investments.